We reply within one business dayGet my quote
Schizophrenia: US-approved treatments and how Gulf families can access them
A plain guide for families in the Gulf, checked against US FDA labels, Gulf drug registers and published medical research.
Reviewed by the Reserve Meds clinical operations team on 17 October 2026.
Schizophrenia: the short answer
The US FDA has approved five medicines on this page for schizophrenia, each for specific patients. Three of them are on at least one Gulf register we checked, so ask your hospital about local supply first. Otherwise the hospital can request a named-patient import. Reserve Meds is a digital health company. We do not diagnose or prescribe.
- US FDA-approved medicines on this page: Cobenfy, Caplyta, Vraylar, Rexulti and Latuda.
- Gulf registration (checked 17 October 2026): see each medicine below.
- Legal route: Local supply where listed; otherwise a named-patient import request filed by the treating hospital.
- Price: Quote on request.
What is schizophrenia?
Schizophrenia is a serious brain illness. People who have it may hear voices that are not there, believe that others are trying to hurt them, or speak in ways that do not make sense. It can make it hard to keep a job or take care of oneself.[1]
Symptoms usually start between ages 16 and 30, often earlier in men. There are three types of symptoms: psychotic symptoms such as hallucinations and delusions, negative symptoms such as withdrawal and flat emotions, and cognitive symptoms such as trouble with attention and decisions.[1]
There is no cure, but medicine can control many symptoms, and people may need to try different medicines to find the one that works best. Therapy, family education, rehabilitation and skills training also help. In the US, several newer oral medicines are approved for schizophrenia.[1, 2]
Schizophrenia in the Gulf
We did not find published data on schizophrenia from the Gulf countries that we could verify on 17 October 2026. The register status for each medicine below shows what we could check.
US FDA-approved medicines for schizophrenia
Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.
- Cobenfy (xanomeline and trospium chloride)
FDA-approved for schizophrenia in adults. It combines xanomeline and trospium in a capsule and works differently from older antipsychotics.[2]
Gulf registers: Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: not found by brand name in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[3, 4]
Country guides: Saudi Arabia, UAE, Kuwait, Egypt, Jordan, Lebanon, Turkey, India, Pakistan - Caplyta (lumateperone)
FDA-approved for schizophrenia in adults, and bipolar depression and add-on treatment of major depression in adults. It is a capsule.[5]
Gulf registers: Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: not found by brand name in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[3, 4]
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, Jordan, Turkey, India, Pakistan - Vraylar (cariprazine)
FDA-approved for schizophrenia in adults and children 13 years and older, and bipolar disorder and add-on treatment of major depression in adults. It is a capsule.[6]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list (as Reagila). Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list (as Reagila). Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[3, 4]
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Egypt, Jordan, India, Pakistan - Rexulti (brexpiprazole)
FDA-approved for schizophrenia in adults and children 13 years and older, and other conditions listed in the label. It is a tablet.[7]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[3, 4]
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Egypt, Jordan, India, Pakistan - Latuda (lurasidone hydrochloride)
FDA-approved for schizophrenia in adults and adolescents 13 to 17 years, and bipolar depression. It is a tablet.[8]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[3, 4]
Country guides: Saudi Arabia, UAE, Kuwait, Egypt, Jordan, India, Pakistan
How families in the Gulf can access these medicines
If the medicine is listed in your country. Ask your specialist and the hospital pharmacy about local supply first. A listing does not mean every hospital stocks the medicine, and another brand of the same medicine may also be registered, but local supply is usually the fastest route and you may not need us.
If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital pharmacy confirms.[9, 10] Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital pharmacy.
Who does what
- Your treating specialist decides whether a medicine is right for the patient and writes the letter.
- The hospital checks local supply, files any import request, and gives the treatment safely.
- The national regulator decides whether to approve the import of a medicine that is not registered.
- The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
- Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.
Documents you will usually need
- A letter from the treating specialist with the diagnosis, past treatments and why the medicine is being considered
- Reports that confirm the diagnosis, such as laboratory, genetic, imaging or pathology results, translated into English where needed
- Recent clinic notes and a list of current medicines
- For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
- Proof of the US FDA approval and the US prescribing information (we can supply these)
We give you a written timeline estimate once we see the hospital file. The regulator, the treatment center and the manufacturer set their own timelines.
What treatment costs
Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.
How Reserve Meds helps
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.
Ask us about treatment for schizophrenia
Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.
Frequently asked questions
Is there an FDA-approved treatment for schizophrenia?
Yes. The medicines on this page have US FDA approval for specific groups of patients: Cobenfy, Caplyta, Vraylar, Rexulti and Latuda. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.
Is Cobenfy available in Saudi Arabia or the UAE?
Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: not found by brand name in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register. A listing in Abu Dhabi does not show federal UAE status.
How can a family in the Gulf get Cobenfy?
Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital pharmacy.
How much does treatment cost?
Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.
Why might a doctor try several medicines?
MedlinePlus explains that people may need to try different medicines to see which works best, and should stay on medicine for as long as the doctor recommends.
Is medicine the only treatment?
No. MedlinePlus lists therapy, family education, rehabilitation and skills training as additional treatments that help with daily life.
Sources for the last two answers: [1] [1]
Sources
Checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital pharmacy confirms the current position before filing.
- MedlinePlus (US National Library of Medicine): Schizophrenia
- DailyMed (US National Library of Medicine): Cobenfy (xanomeline and trospium chloride) US prescribing information, version published 21 August 2026
- SFDA: Drugs List, public register (all 9,173 entries checked by brand name on 17 October 2026)
- Department of Health Abu Dhabi: drug code list Drugs.xlsx (release 26 September 2026, effective 2 October 2026)
- DailyMed (US National Library of Medicine): Caplyta (lumateperone) US prescribing information, version published 1 June 2026
- DailyMed (US National Library of Medicine): Vraylar (cariprazine) US prescribing information, version published 20 August 2026
- DailyMed (US National Library of Medicine): Rexulti (brexpiprazole) US prescribing information, version published 28 May 2026
- DailyMed (US National Library of Medicine): Latuda (lurasidone hydrochloride) US prescribing information, version published 14 January 2026
- SFDA: Special Access Program (SAP) guidance, version 1.0
- NHRA Bahrain: Circular No. (41) of 2020, procedures for importing non-registered medicines and pharmaceutical products
Related
- Major depressive disorder
- Treatment-resistant depression
- Named-patient access in the Gulf, explained
- Answers to common access questions
- Cross-border disclosures
- اقرأ هذه الصفحة بالعربية
- यह पृष्ठ हिंदी में पढ़ें
This page is general health information, not medical advice. It does not replace a consultation with your doctor.